Ondine Biomedical Inc. (OBI.L)
- Previous Close
8.75 - Open
0.00 - Bid 8.00 x --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 13.30 - Volume
11,590,000 - Avg. Volume
153,736 - Market Cap (intraday)
39.891M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
55.00
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of treat infections, including those caused by drug-resistant pathogens antimicrobial therapies in Canada and internationally. It threats protect patients, reduce healthcare costs, and preserve the effectiveness of antibiotics. In addition, the company products pipeline platform includes burns, ventilator tube, and sinus; and Serious, Chronic wounds, Chronic sinusitis, Ventilator-associated pneumonia VAP, Central line bloodstream infections CLABSI, as well as Catheter-associated urinary tract infection CAUTI. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
ondinebio.comRecent News: OBI.L
View MorePerformance Overview: OBI.L
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OBI.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OBI.L
View MoreValuation Measures
Market Cap
36.57M
Enterprise Value
36.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.64
Price/Book (mrq)
3.57k
Enterprise Value/Revenue
40.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-130.98%
Return on Equity (ttm)
-426.20%
Revenue (ttm)
2.05M
Net Income Avi to Common (ttm)
-19.1M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
9.77M
Total Debt/Equity (mrq)
2.44%
Levered Free Cash Flow (ttm)
-9.61M